EUVIMEDEUVIMED entdecken
Multizentrische Studie

Survey of cryoprecipitate production and cryoprecipitate and fibrinogen concentrate utilization in North America: Variable practices observed from July 2016 to June 2021, The BEST Collaborative Study

Wen Lu iD, Umesh Singh, Alyssa Ziman iD, Ralph Vassallo iD, Jessica L Poisson, Andrew W Shih, Jay S Raval, Jessica Grandoni, Cyril Jacquot iD, Marc Germain, Nancy M Dunbar iD, Claudia Cohn iD und 2 weitere

Transfusion · 2025

DOI: 10.1111/trf.18434 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Transfusion, 2025. Verfasst von Wen Lu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Fibrinogen, Factor VIII. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cryoprecipitated antihemophiliac factor (cryo) is primarily used to replenish fibrinogen in acquired coagulopathy. Little has been reported about its usage patterns within hospitals with respect to patient population, frequency of use, and dosing. Study design and methods Cryo production and usage data were collected over 5 years from July 1, 2016, to June 30, 2021, from nationally based blood collection centers in the United States (U.S. n = 2) and Canada ( n = 2) and from eight large academic hospitals, respectively. Usage data for a similar product, purified fibrinogen concentrate were also collected from four hospitals.

Results

Two U.S. blood collectors reported increases in cryo production normalized to total whole blood collections from 17.4% in 2016 to 22.3% in 2021 and from 16.4% in 2016 to 20.2% in 2021. In contrast, in Canada cryo manufacturing increased slightly in one region (11.3%–12.9%) and decreased (8.0%–2.0%) in the other. Cryo utilization, defined as numbers of patients treated normalized to the inpatient census, and dose administered per patient did not consistently increase and differed significantly between hospitals participating in the study ( p < .0001). Likewise, the departments that most frequently transfused cryo varied between hospitals. Similarly, variations in practice were observed for fibrinogen concentrate usage.

Conclusion

While much of Canada and Europe have moved towards using fibrinogen concentrate, two large U.S. collectors have increased cryo distribution. The lack of standardization and variability in the clinical practice regarding the use of cryo and fibrinogen concentrate reported by study sites may be attributable to practitioner preference, availability, and/or cost rather than adherence to published evidence or guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FibrinogenFactor VIIIHumansCanadaUnited StatesSurveys and QuestionnairesNorth America

Stichwörter der Autor:innen

cryoprecipitatedistributionfibrinogen concentratetransfusionutilization

Substanzen

FibrinogenFactor VIIIcryoprecipitate coagulum

Autor:innen und Institutionen

  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • American Red Cross, Washington D.C., USA.
  • Wing-Kwai and Alice Lee-Tsing Chung Transfusion Service, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, California, Los Angeles, USA.
  • Vitalant Medical Affairs, Scottsdale, Arizona, USA.
  • Department of Pathology, Duke Health, Durham, North Carolina, USA.
  • Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

ORCID-Profile: Wen Lu, Alyssa Ziman, Ralph Vassallo, Cyril Jacquot, Nancy M Dunbar, Claudia Cohn, Pampee Young

Zitieren

APA

Lu, W., Singh, U., Ziman, A., Vassallo, R., Poisson, J. L., Shih, A. W., Raval, J. S., Grandoni, J., Jacquot, C., Germain, M., Dunbar, N. M., Cohn, C., Young, P., & Biomedical Excellence for Safer Transfusion Collaborative (2025). Survey of cryoprecipitate production and cryoprecipitate and fibrinogen concentrate utilization in North America: Variable practices observed from July 2016 to June 2021, The BEST Collaborative Study. Transfusion. https://doi.org/10.1111/trf.18434

Vancouver

Lu W, Singh U, Ziman A, Vassallo R, Poisson JL, Shih AW, et al. Survey of cryoprecipitate production and cryoprecipitate and fibrinogen concentrate utilization in North America: Variable practices observed from July 2016 to June 2021, The BEST Collaborative Study. Transfusion. 2025. doi:10.1111/trf.18434

BibTeX
@article{Lu2025,
  author = {Lu, Wen and Singh, Umesh and Ziman, Alyssa and Vassallo, Ralph and Poisson, Jessica L and Shih, Andrew W and Raval, Jay S and Grandoni, Jessica and Jacquot, Cyril and Germain, Marc and Dunbar, Nancy M and Cohn, Claudia and Young, Pampee and Biomedical Excellence for Safer Transfusion Collaborative, Biomedical Excellence for Safer Transfusion Collaborative},
  title = {Survey of cryoprecipitate production and cryoprecipitate and fibrinogen concentrate utilization in North America: Variable practices observed from July 2016 to June 2021, The BEST Collaborative Study},
  journal = {Transfusion},
  year = {2025},
  doi = {10.1111/trf.18434}
}
Kostenlos starten →